The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?

Filippo Crea, Gregory Angelo Sgueglia

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

1 Citazioni (Scopus)

Abstract

High serum cholesterol levels are associated with death from coronary heart disease and statin therapy has been demonstrated to effectively lower low-density lipoprotein (LDL) cholesterol and reduce coronary events in broad sections of the population. Recently, the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized 17 802 apparently healthy individuals, with levels of LDL cholesterol below current treatment thresholds but with elevated levels of high-sensitivity C-reactive protein, to rosuvastatin 20 mg daily, or placebo. At a median follow-up of almost 2 years, compared to placebo, rosuvastatin treatment was associated with a significant reduction in the incidence of major cardiovascular or cerebrovascular events, that is, almost twice the magnitude found in previous statin trials. Such a noteworthy finding is discussed herein
Lingua originaleEnglish
pagine (da-a)66-70
Numero di pagine5
RivistaJournal of Cardiovascular Medicine
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • coronary heart disease
  • low-density lipoprotein
  • statin therapy

Fingerprint Entra nei temi di ricerca di 'The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?'. Insieme formano una fingerprint unica.

Cita questo